History

 

1999

Oasmia Pharmaceutical AB founded.

2004

Clinical trials on Paclical initiated.

2005

Clinical trials on Paccal Vet® initiated.

2006

Oasmia obtains SME status from EMA.

Paclical granted orphan drug status by EMA.

2007

Clinical phase III studies on Paccal Vet initiated.

2008

Clinical phase III studies on Paclical initiated.

2009

Distribution agreement entered into with Abbott Laboratories for Paccal Vet in the US and Canada.

The US Food and Drug Administration (FDA) grants Paclical orphan drug status for the treatment of ovarian cancer in the US.

2010

Oasmia changes trading platform from NGM Equity to NASDAQ Stockholm.

Oasmia submits registration documentation for Paccal Vet to FDA (US).

2011

Oasmia listed on Frankfurt Stock Exchange.

Agreement entered into with Baxter Oncology GmbH for contract manufacturing.

Results from interim analysis demonstrate that Paclical meets the clinical requirement of non-inferiority vis-à-vis Taxol®.

2012

FDA grants MUMS designation to Paccal Vet for the treatment of mammary carcinoma and to Doxophos Vet for the treatment of lymphoma.

2013

Development of OAS-19 initiated, the first drug candidate with two active cytostatics in one infusion.

Oasmia and Pharmasyntez sign an agreement regarding the rights to Paclical in Russia and the CIS.

2014

Paccal Vet obtains conditional approval from the FDA.

Oasmia’s production facility approved by both the FDA and EMA.

Oasmia moves to the Mid Cap segment of NASDAQ Stockholm.

2015

Paclical receives market approval for treatment of ovarian cancer in Russia.

Oasmia regains rights to Paccal Vet and Doxophos Vet from Zoetis Inc.

Oasmia listed on Nasdaq Capital Market in New York.

2016

Oasmia applies for market approval for Apealea® (Paclical) in EU.

The company receives positive clinical results for XR17.

Oasmia applies for market approval for Doxophos in Russia.

Clinical trials on Docecal initiated.

New cancer project acquired from Karo Pharma.

2017

Positive results for Apealea (Paclical) reported for breast cancer with weekly treatment.

The company enters into a new exclusive marketing and distribution agreement with Hetero Group for Russia and the CIS.

Doxophos approved in Russia.

Paclical approved in Kazakhstan.

2018

All patients treated in pivotal study on Docecal.

The company’s veterinary assets are transferred to the American subsidiary AdvaVet Inc.

The European Commission grants approval for Apealea.

2019

Oasmia receives positive opinion from EMA to add efficacy data to the approved Apealea product information.

Extraordinary General Meeting appoints new Board, which initiates a review of the most important areas impacting Oasmia’s value.

Oasmia strengthens the management team.

Oasmia reports on the results from the two clinical studies using Docecal in patients with metastatic breast cancer.

Oasmia announces the formation of its Scientific and Business Advisory Boards.

Oasmia is delisted from NASDAQ in the US to reduce complexity and costs.